Innovent Biologics: Product revenue is expected to grow by 44.6% to 11.896 billion yuan in 2025. The company's product portfolio has expanded to 18 marketed products.

LightningPacketLoss · 2026-03-26T22:34:06+00:00

Cinda Biologics announced its 2025 annual report, with total revenue of 13.042 billion yuan, a year-on-year increase of 38.4%. Gross profit reached 11.286 billion yuan, and it achieved an IFRS net profit of 814 million yuan for the first time, demonstrating a significant improvement in profitability. The oncology sector and integrated product lines drove business growth, and the company will continue to expand its product portfolio and enter global Phase III clinical trials.

LightningPacketLoss

2026-03-26 22:34:06

Abstract generation in progress

Cinda Biotech announced its full-year results for the period ending December 31, 2025. The company achieved a total revenue of 13.042 billion yuan, a 38.4% increase year-over-year. Gross profit was 11.286 billion yuan, up 42.6%. For the first time, the company reported an annual profit, with IFRS net profit of 814 million yuan, compared to a loss of 94.63 million yuan in 2024, marking a significant improvement in profitability.

In the financial review, product revenue reached 11.896 billion yuan, a 44.6% increase, mainly driven by sustained leadership in the oncology field and rapid expansion of the comprehensive product line. Although licensing fee income decreased to 957 million yuan (from 1.1 billion yuan in 2024), the overall revenue growth continued to boost the company’s profitability. Non-IFRS net profit surged to 1.723 billion yuan, a 419.6% increase.

In the management discussion and analysis, it was mentioned that in 2025, the company implemented a “dual-wheel drive” strategic upgrade, with oncology and comprehensive product lines jointly driving business growth. Three core innovative assets have entered or are about to enter global Phase III clinical trials, laying a foundation for future growth. The company’s product portfolio has expanded to 18 marketed products, of which 12 are included in the China National Reimbursement Drug List (NRDL), further strengthening its market position.

(Cinda Biotech Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes